Connect with us

Technology

Promise Bio Emerges from Stealth with $8.3M Seed Investment to Transform Precision Medicine for Immune-Mediated Diseases

Published

on

Company unveils breakthrough platform that integrates epiproteomics and AI to identify predictive biomarkers for personalized treatments and support drug development

TEL AVIV, Israel, Dec. 16, 2024 /PRNewswire/ — Promise Bio, a startup transforming immune-mediated disease treatment with advanced precision medicine solutions, today announced its emergence from stealth with an $8.3 million seed investment. This funding will accelerate the development of Promise Bio’s computational platform, which uses epiproteomics and artificial intelligence to predict patient treatment responses and support drug research and development.

“Current biological treatments for autoimmune diseases don’t work in all patients, with only 30-40% of patients achieving significant remission. At Promise Bio, our mission is to eliminate the trial-and-error approach by introducing tools for data-driven decisions,” said Ronel Veksler, Co-founder & CEO of Promise Bio. “The key to addressing this challenge lies in focusing on the right biological data—proteins, the building blocks of our body. It’s not just about protein levels but understanding the changes they undergo after formation. The PROMISE (Protein Modification Integrated Search Engine) platform does exactly that, enabling us to get closer to bringing precision medicine to diseases that currently lack effective tools.”

Promise Bio’s innovative platform is rooted in years of foundational research conducted by Dr. Assaf Kacen, Co-Founder & CTO of Promise Bio, in the lab of Prof. Yifat Merbl, Scientific Co-Founder of the company, at the Weizmann Institute of Science. The groundbreaking research into protein modifications and immune response, featured in Nature Biotechnology in 2023, laid the foundation for developing Promise Bio’s computational platform. Dr. Kacen built on this research to create a system that enables broad-scale profiling of dozens of post-translational modifications (PTMs) from mass-spectrometry data without needing customized chemical enrichment or additional lab procedures.

“Determining the change in the protein level or relying on just blood count caused by a complex immune response is like looking at a black-and-white TV screen with poor resolution,” said Dr. Assaf Kacen, Co-Founder & CTO of Promise Bio. “Our platform extracts modifications that occur to the proteins resulting from the disease; those specific changes inform us about aberrations in protein function or regulation. Interpreting it with machine learning approaches is like watching a colored TV with an unparalleled high-resolution view of the underlying biology.”  

The $8.3 million seed investment, led by Awz Ventures, and with funding via AION Lab’s venture seeding track from AstraZeneca and Pfizer, provides Promise Bio with crucial financial backing to accelerate the development of its platform. This funding, along a grant from the Israel Innovation Authority, strengthens the company’s ability to scale its cutting-edge technology and expand its research capabilities.

The strategic partnerships with the two leading biopharmaceutical companies offer more than just financial support—they bring invaluable industry expertise, access to global networks, and collaboration opportunities to integrate Promise Bio’s platform into drug development pipelines. Together, these resources position the company to rapidly advance precision medicine solutions for immune-mediated diseases while building the world’s largest PTM database, a vital resource for future medical breakthroughs.

“At AION Labs, we are committed to fostering innovation that can reshape healthcare,” said Mati Gill, CEO of AION Labs. “Promise Bio’s integration of epiproteomics and AI holds immense promise for transforming treatment approaches in immune-mediated diseases. This first AION seeding track investment aligns with our mission to support breakthrough computational and AI science in our field, and we’re excited to be part of this journey toward impactful change for patients worldwide.”

“Awz is honored to support Promise Bio’s transformative approach to addressing immune-mediated diseases,” said Yaron Ashkenazi, Founder & Managing Partner of Awz, a global investment firm focused on multi-use innovations across deep-tech, medtech, and more. “Awz has deep confidence in Promise Bio’s visionary leadership and distinctive strategy, which we believe are poised to set new standards in the field. Our investment reflects our commitment to backing this transformative team with the potential to advance personalized medicine and make a lasting impact on patient outcomes.”

Through the Awz X-Seed Hub in Tel Aviv, Awz’s Active Capital strategy provides Promise Bio with multi-stage investment, hands-on mentorship, strategic partnerships, and preparation for future funding rounds, including the unique joint investment from leading pharmaceutical companies via AION Labs.

About Promise Bio

Promise Bio is a pioneering precision medicine company focused on transforming the management of immune-mediated diseases through epiproteomics and artificial intelligence. Built on groundbreaking research from the Weizmann Institute of Science, Promise Bio analyzes proteins and their post-translational modifications (PTMs) with exceptional precision. This proprietary technology allows for large-scale PTM profiling, helping researchers uncover disease mechanisms, tailor therapies, and discover new drug targets. For more information, visit www.promise.bio.

For media inquiries please contact media@promise.bio

View original content:https://www.prnewswire.com/news-releases/promise-bio-emerges-from-stealth-with-8-3m-seed-investment-to-transform-precision-medicine-for-immune-mediated-diseases-302331966.html

SOURCE Promise Bio

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

AGM Group Holdings Inc. Announces Strategic Partnership with Canada’s Nowlit to Expand High-Performance Computing Capabilities

Published

on

By

BEIJING, Dec. 20, 2024 /PRNewswire/ — AGM Group Holdings Inc. (“AGM Holdings” or the “Company”) (NASDAQ: AGMH), an integrated technology company specializing in the assembling and sales of high-performance hardware and computing equipment, announced today that the Company has signed an investment intention agreement (the “Agreement”) with its Canadian partner, NOWLIT Solutions Corp. (“Nowlit”), a prominent energy technology company focused on developing energy solutions and data center infrastructure in Canada, to provide green energy data center and cryptocurrency computing power. This initiative aligns strategically with AGM Holdings’ long-term expansion plan in the rapidly evolving artificial intelligence and data center market in North America.

Pursuant to the Agreement, Nowlit plans to contribute its existing 50 megawatts (MW) data center assets to AGM Energy Corp. (“AGM Energy” or the “JV”), the Canadian joint venture co-founded by AGM Holdings and Nowlit. Led by Nowlit’s founder, Mr. Ma, the JV is set to expand its capacity significantly. The initial 50MW contribution will enable the data center to host over 6,800 high-performance computing servers, providing an estimated computing power of 2,457 petahashes (P).

AGM Energy aims to develop additional data centers in Canada incrementally over the next two years, adding an average of 20MW per month, with a total projected capacity of 375MW. Additionally, the JV aims to leverage upstream and downstream industry partnerships to enhance computing power. The total computing power capacity of these data centers is expected to reach 18,427P within two years.

This significant milestone underscores AGM Holdings’ commitment to strengthening its market presence in the fast-growing data center sector. By capitalizing on the increasing demand for digital assets and leveraging its expertise in hardware and software solutions, the Company is well-positioned to capture emerging opportunities brought forward by the latest artificial intelligence technology revolution, driving sustainable growth and value creation for its stakeholders.

About NOWLIT Solutions Corp.

Established in 2013, NOWLIT Solutions Corp. is a high performance computing and data center supplier based in Canada. It offers complete solution including all hardware, hosting and initial setup for new and experienced servers. It is also committed to supporting the blockchain ecosystem by offering hardware, software and a variety of solutions and services. It has invested in large-scale oil and gas fields and is involved in the construction and operation of informatization infrastructure such as third-party data center machine rooms and bitcoin mining farms. For more information, please visit https://nowlit.com/.

About AGM Group Holdings Inc.

AGM Group Holdings Inc. (NASDAQ: AGMH) is an integrated technology company specializing in the assembling and sales of high-performance hardware and computing equipment. With a mission to become a key participant and contributor in the global blockchain ecosystem, AGMH focuses on the research and development of blockchain-oriented Application-Specific Integrated Circuit (ASIC) chips, the assembling and sales of high-end crypto miners for Bitcoin and other cryptocurrencies. For more information, please visit www.agmprime.com.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “approximates,” “assesses,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the U.S. Securities and Exchange Commission.

For more information, please contact:

AGM Group Holdings Inc.
Email: ir@agmprime.com 
Website: http://www.agmprime.com

Ascent Investor Relations LLC
Tina Xiao
President
Phone: +1-646-932-7242
Email: investors@ascent-ir.com

View original content:https://www.prnewswire.com/news-releases/agm-group-holdings-inc-announces-strategic-partnership-with-canadas-nowlit-to-expand-high-performance-computing-capabilities-302337049.html

SOURCE AGM Group Holdings Inc.

Continue Reading

Technology

Tiina A. Lantto, Ph.D., and Max C. Moseley, MSc, Join The Acta Group’s Brussels and Manchester Offices

Published

on

By

The Acta Group (Acta®) is pleased to announce the expansion of our global scientific and regulatory capabilities with the appointments of Tiina A. Lantto, Ph.D., Regulatory Scientist and Toxicologist in our Brussels, Belgium, office, and Max L. Moseley, MSc, Regulatory Specialist in our Manchester, England, office.

WASHINGTON, Dec. 20, 2024 /PRNewswire-PRWeb/ — The Acta Group (Acta®) is pleased to announce the expansion of our global scientific and regulatory capabilities with the appointments of Tiina A. Lantto, Ph.D., Regulatory Scientist and Toxicologist in our Brussels, Belgium, office, and Max L. Moseley, MSc, Regulatory Specialist in our Manchester, England, office.

With offices in the United States, the UK, and the EU, Acta assists companies with complex registration and compliance issues under multiple regulatory schemes worldwide.

Dr. Tiina A. Lantto provides seasoned, sophisticated toxicology and regulatory guidance for worldwide chemical registration and compliance programs, with particular expertise in European chemical regulatory programs, including all aspects of the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) regulation. Dr. Lantto’s two decades of experience as a toxicologist and regulatory scientist include serving as a regulatory science researcher and dossier evaluator with the European Chemicals Agency’s (ECHA) Classification and Prioritisation Unit and Evaluation Unit, as a toxicologist for a global fragrance and flavor company, as a consultant to international chemical and petrochemical companies, and as a researcher and instructor at the University of Helsinki. Dr. Lantto holds an MSc in Animal Biotechnology from the University of Eastern Finland and a Ph.D. in Pharmaceutical Biology from the University of Helsinki.

Max L. Moseley, MSc assists clients in the United Kingdom (UK), the European Union (EU), and worldwide with global chemical regulatory compliance while keeping a keen focus on attendant business impacts. Within the EU and UK REACH frameworks, he concentrates on the full spectrum of support services for co-registrants and lead registrants, including performing data gap assessments, authoring robust study summaries (RSS), completing quantitative structure-activity relationship (QSAR) assessments, and designing integrated testing strategies. Mr. Moseley offers clients particular expertise in green chemistry, sustainability, life cycle analysis, Greenhouse Gas Protocol Carbon Accounting standards, and meeting the objectives of the EU Chemicals Strategy for Sustainability (CSS). Mr. Moseley earned a BS in Chemistry and an MSc in Green Chemistry and Sustainable Industrial Technology, both from the University of York, England. He has spent the decade since as a trusted chemical regulatory and business consultant.

Acta is a scientific, business, and regulatory consulting firm staffed by experts who assist companies making or using chemicals to commercialize and sustain their products globally. With offices in the United States, the UK, and the EU, Acta assists companies with complex registration and compliance issues under multiple regulatory schemes worldwide. For more information, visit our website at http://www.actagroup.com. For timely updates and thoughtful analysis on developments under REACH and UK REACH, visit and subscribe to Acta’s REACHblog®, http://www.reachblog.com.

Acta is the consulting affiliate of Bergeson & Campbell, P.C. (B&C®), a Washington, D.C. law firm focusing on conventional, biobased, and nanoscale industrial, agricultural, and specialty chemical product approval and regulation, product defense, and associated business issues.

Media Contact

Heidi Lewis, The Acta Group, 202-557-3812, hlewis@actagroup.com, www.actagroup.com

View original content to download multimedia:https://www.prweb.com/releases/tiina-a-lantto-phd-and-max-c-moseley-msc-join-the-acta-groups-brussels-and-manchester-offices-302336956.html

SOURCE The Acta Group

Continue Reading

Technology

Playtika Teams Up with IGT to Bring World-Class Slots to Social Casino Games

Published

on

By

IGT slot titles meet Playtika’s iconic social casino portfolio: Slotomania, Caesars Slots, and House of Fun

HERZLIYA, Israel, Dec. 20, 2024 /PRNewswire/ — Playtika (NASDAQ: PLTK), a leader in mobile gaming and interactive entertainment, has announced a partnership with IGT (NYSE:IGT), a global gaming leader. This collaboration brings several of IGT’s most popular renowned slot themes to Playtika’s category-leading social casino games, offering players an exciting new way to enjoy their favorite casino slots virtually, free of charge.*

Starting this month and rolling into 2025, IGT slot titles will appear in Slotomania, Caesars Slots, and House of Fun. The first fan-favorite, Cleopatra II, will debut in Slotomania beginning December 26, 2024, with more top-performing IGT slots slated to follow throughout the next year.

“We are constantly looking for ways to engage new players and are thrilled to announce our strategic content partnership with IGT,” said Amnon Calev, Executive General Manager of Slots Central and Slotomania at Playtika. “As leaders in the social casino industry, it was only natural for us to collaborate with the creators of some of the most iconic games in the gaming industry and bring the best content into our social casino game.”

IGT’s President of Global Gaming, Nick Khin, echoed the excitement: “By partnering with Playtika, IGT can extend the reach of its player-favorite games portfolio and offer popular games such as Cleopatra II in a free-to-play format via Playtika’s iconic social casino games. This collaboration creates new opportunities for a global audience of players to immerse themselves in the thrill of IGT slots in a virtual, social setting.”

Cleopatra II will launch in Slotomania this December, accompanied by a multi-platform marketing campaign, and players can look forward to discovering which popular IGT games are anticipated to launch in Caesars Slots and House of Fun. Download all three games, which are available for free in the Apple Store and Google Play store to experience the virtual slots, straight from the Vegas casino floor to your phone. Playtika’s social casino games are designed for entertainment purposes only, with no real money rewards.

About Playtika
Playtika Holding Corp. (NASDAQ: PLTK) is a mobile gaming entertainment and technology market leader with a portfolio of multiple game titles. Founded in 2010, Playtika was among the first to offer free-to-play social games on social networks and, shortly after, on mobile platforms. Headquartered in Herzliya, Israel, and guided by a mission to entertain the world through infinite ways to play, Playtika has employees across offices worldwide.

About IGT
IGT (NYSE:IGT) is a global leader in gaming. We deliver entertaining and responsible gaming experiences for players across all channels and regulated segments, from Lotteries and Gaming Machines to Sports Betting and Digital. Leveraging a wealth of compelling content, substantial investment in innovation, player insights, operational expertise, and leading-edge technology, our solutions deliver unrivaled gaming experiences that engage players and drive growth. We have a well-established local presence and relationships with governments and regulators in more than 100 jurisdictions around the world and create value by adhering to the highest standards of service, integrity, and responsibility. IGT has approximately 11,000 employees. For more information, please visit www.igt.com.

* *Playtika’s social casino games are free-to-play. Optional purchases of virtual items (including random items) are available in the game and can be disabled in device settings. No real-money rewards are offered.

View original content to download multimedia:https://www.prnewswire.com/news-releases/playtika-teams-up-with-igt-to-bring-world-class-slots-to-social-casino-games-302336730.html

SOURCE Playtika Holding Corp.

Continue Reading

Trending